Dr. Paras Satadeve
Consultant (Hemato-Oncology & BMT)
Dr. Paras Satadeve is a Clinical Hematologist, with advanced training in benign hematology, hemato-oncology, and bone marrow transplantation. He has strong expertise in managing chronic myeloid leukemia and complex hematologic disorders using evidence-based, globally aligned protocols. Actively involved in clinical research, Dr. Satadeve has multiple national and international publications and presentations. His patient-centered approach, combined with his recent association with BMT Next, strengthens the center’s commitment to advanced, ethical, and outcome-driven hematology care.
Education
- MBBS: 2015
- MD (General Medicine): 2020, Gandhi Medical College, Bhopal, MP, India.
- DM (Clinical Hematology): 2025, All India Institute of Medical Sciences (AIIMS), Rishikesh, India.
- European Hematology Association (EHA) Certified Hematologist
Work Experience
- Current Position: Consultant, Hemato-Oncology & Bone Marrow Transplants , BMT Next (Marengo Asia Hospitals)
- Former Associate Consultant at Yashoda Hospitals Hitec City Hyderabad.
- Senior Resident (2021–2022): Clinical Hematology, All India Institute of Medical Sciences (AIIMS), Bhopal, India.
- Senior Resident (2020–2021): Department of General Medicine, Gandhi Medical College, Bhopal, MP, India.
- Trained in Benign Hematology, Hemato-oncology & Bone marrow transplants (BMT).
Research Activities
- Principal Investigator: A prospective exploratory blinded end-point assessment study comparing two different doses of generic dasatinib in newly diagnosed chronic myeloid leukemia (CML) patients. This was part of his M.D. Medicine thesis.
- Sub-Investigator:
- A Phase IIIb, multicenter, open-label, randomized study (ASC4START) of oral asciminib versus nilotinib for newly diagnosed Philadelphia Chromosome Positive CML in chronic phase.
- A Phase IIa study of HT-6184 in patients with myelodysplastic syndrome (MDS) and symptomatic anemia.
- A Phase 3, randomized, double-blind study (VAYHIT2) of lanalumab versus placebo, plus eltrombopag, for primary immune thrombocytopenia (ITP).
- A Phase 3 study (PACIFICA) of pacritinib in patients with myelofibrosis.
Publications
- A randomized controlled study from India comparing the early treatment response and safety of lower dose (70 mg/day) versus standard dose (100 mg/day) of generic dasatinib in chronic phase CML.
- A randomized controlled study from India comparing the molecular response and safety of lower dose (70 mg) versus standard dose (100 mg) of generic dasatinib in newly diagnosed CML-CP patients.
- A case report of t(1;12)(p31;q13) cytogenetic abnormality in a patient of idiopathic hypereosinophilic syndrome.
- “Marked leukemoid reaction preceded the onset of meningitis: A case report,” published in the Journal of Hematology and Allied Sciences.
- “Real-World Data of Molecular Response Using Different Dosage of Upfront Generic Dasatinib in Chronic Phase Chronic Myeloid Leukemia: Single-Center Experience from India,” a conference abstract published in the journal Blood.
- “Outcome of Childhood and Adolescents and Young Adults ALL Treated with ALL IC-BFM 2009 Protocol-A Single-Center Experience in India,” a study published in a Springer journal.Â
Conference Presentations
Dr. Satadeve has several conference papers accepted for presentation:
- EHA Congress 2025 in Milan, Italy (Oral Paper) and received a travel grant for it.
- EHA Congress 2024 in Madrid, Spain (Poster Presentation).
- Hematocon 2024 in Nagpur, India (Oral Abstract).
- Hematocon 2023 in Bhubaneswar, India (Oral Abstract).
- HOPE ASIA 2023 in New Delhi, India (Poster Presentation).
Memberships
He is a member of the following professional organizations:
- Indian Society of Hematology and Blood Transfusion (ISHBT).
- European Hematology Association (EHA).
- European Society for Medical Oncology (ESMO)
